Phase 1Terminated
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
- Sponsor
- Kyowa Kirin Co., Ltd. (Industry)
- Enrollment
- 22 enrolled
- Conditions
- Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Primary Peritoneal Neoplasm
- Interventions
- KHK2866; Gemcitabine and Carboplatin; paclitaxel; pegylated liposomal doxorubicin
- Ages
- adults, older adults
- Registry
- NCT01279291
Full record on ClinicalTrials.gov
From the registry
This is a two-part, Phase 1, open-label, multicenter, dose escalation study of KHK2866 as monotherapy in patients with advanced solid tumors, and in combination with chemotherapy in subjects platinum-sensitive and platinum-resistant ovarian cancer.
Primary outcomes
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
History
Last registry update
Primary completion
Registered
Started